Last updated on August 2019

A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease

Brief description of study

The STRONG SCD study is being conducted to help advance research into an oral investigational drug for people with sickle cell disease (SCD). It is evaluating the investigational drug—compared to placebo (looks like the investigational drug but does not contain any active ingredient)—to understand how it affects people with SCD and whether it can lessen complications, including pain crises.

Sickle cell disease is an inherited red blood cell disorder that causes red blood cells to deform into a sickle shape, impacting blood flow to organs and tissues. The investigational drug is designed to increase the production of cGMP, something the body produces naturally.

Researchers believe that increasing cGMP may help improve blood flow and reduce inflammation while boosting the number of healthy red blood cells in people with sickle cell disease. By doing so, they believe that more nutrients will be able to get to the critical organs that need them, lessening the risk for disease complications.

Study participation provides the opportunity to help advance knowledge and contribute to research that may help the SCD community.

For more information and to see if you may be eligible to participate, visit our study website:


Clinical Study Identifier: TX226734

Find a site near you

Start Over

Omega Research Maitland, LLC

Located in: Orlando, Florida United States
  Connect »